PSMC3

Across TCGA pan-cancer cohorts, PSMC3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PSMC3 data layer compared with 28 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PSMC3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSMC3 expression acts as an unfavorable survival marker.

OV, BLCA, and HNSC are the cancer types where PSMC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.209	0.541	.020	18	view →
BLCA	OS	Median	III,IV	0.051	0.684	<.001	12	view →
HNSC	OS	Median	All	0.099	0.768	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PSMC3–OV (DFS)

Open the OV breakdown →